Phase i study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 128-133

  Daniel A Morgenstern, ^a   Monia Marzouki, ^b   Ute Bartels, ^a   Meredith S Irwin, ^a   Giselle L S Sholler, ^c   Janet Gammon, ^a   Rosanna Yankanah, ^a   Bing Wu, ^a   Yvan Samson, ^b   Baruchel, Sylvain ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Anti angiogenesis; mTOR; Phase I; Rapamycin; Sirolimus; Vinblastine

Indexed keywords

CHOLESTEROL; RAPAMYCIN; S6 KINASE; TRIACYLGLYCEROL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VINBLASTINE; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ABDOMINAL PAIN; ACALCULOUS CHOLECYSTITIS; ADOLESCENT; ADULT; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LOADING DRUG DOSE; MUCOSA INFLAMMATION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINBLASTINE; YOUNG ADULT;

EID: 84891687527     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24656     Document Type: Article

References (30)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-894.
3. Gallicchio MA, van Sinderen M, Bach LA. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res 2003;35:822-827.
4. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7:1758-1764.
5. Johnsen JI, Segerstrom L, Orrego A, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008;27: 2910-2922.
6. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003;22:9282-9287.
7. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799-805.
8. Dilling MB, Dias P, Shapiro DN, et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 1994;54:903-907.
9. Wagner F, Henningsen B, Lederer C, et al. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients. Eur J Cancer 2012;48:2442-2450.
10. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-2411.
11. Petricoin EF, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-3440.
12. Cen L, Arnoczky KJ, Hsieh F-C, et al. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 2007;20:936-946.
13. McBride SM, Perez DA, Polley M-Y, et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 2010;97:33-40.
14. Mueller S, Phillips J, Onar-Thomas A, et al. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-Oncology 2012;14:1146-1152.
15. Houghton PJ, Morton CL, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 2010;9:101-112.
16. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012;30:1358-1363.
17. Marimpietri D, Brignole C, Nico B, et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 2007;13:3977- 3988.
18. Marimpietri D, Nico B, Vacca A, et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005;24:6785-6795.
19. Rapamune Prescribing Information. 2012. http://labeling.pfizer.com/showlabeling.aspx?id1/4139. Published December 2012. Accessed 25 February 2013.
20. Kasap B. Sirolimus in pediatric renal transplantation. Pediatr Transplant 2011;15:673-685.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
22. Schubert M, Venkataramanan R, Holt DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004;4:767-773.
23. Goyal RK, Han K,Wall DA, et al. Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. Biol Blood Marrow Transplant 2013;19:569-575.
24. Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: Evidence of activity in rhabdomyosarcoma. Cancer 2002;94:3263-3268.
25. Kuttesch JF, Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (navelbine) in recurrent or refractory pediatric malignancies: AChildren's Oncology Group study. Pediatr Blood Cancer 2009;53:590-593.
26. Baruchel S,Wu B, Mokhtari RB, et al. Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. J Clin Oncol 2011;29:abstr. 9502.
27. Ebos JML, Bocci G, Man S, et al.Anaturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004;2:315-326.
28. Ebos JML, Lee CR, Bogdanovic E, et al. Vascular endothelial growth factor mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008;68:521-529.
29. Ebos JML, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent, correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007;104: 17069-17074.
30. Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011;20:381-394.